Navigation Links
SPO Announces Completion of Rebranding Program

SPO Announces Completion of Rebranding Program -- NEW YORK, November 4, 2010 /PRNewswire-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Web Site, Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, General Sports, New Products & Services Click to view news release full screen  

SPO Announces Completion of Rebranding Program


NEW YORK, November 4, 2010 /PRNewswire-FirstCall/ --

- Company Positioned for Growth via Consumer-Related Wellness Applications

SPO Medical Inc. (SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, today announced it has completed its rebranding program so it can operate primarily on consumer-related wellness applications. The company will now focus on several vertical applications based on its proprietary technology platform. Moving forward, SPO will operate divisionally through the SPO Wellness(TM), SPO Medical, SPO Baby and SPO Security product lines. Additionally, a new corporate web site and company logo has been launched that can be viewed at

Michael Braunold, President and Chief Executive Officer of SPO commented, "This is an important milestone for the company and its shareholders. With our ability to now focus on vertical market opportunities, we can maximize the value of our technology through commercial partnerships to promote our consumer product lines. Our experience in developing and launching several successful medical product offerings enables us to now effectively focus on mass-market, consumer opportunities going forward. Our primary market is in the wellness space and we are in the latter stages of preparing for launch of our new SPO Wellness(TM) product line. We achieved this through our partnership with Brewer Sports International (BSI), the world's fastest growing multi-faceted advisory firms with a focus on the business of sports and wellness."

As part of this launch program, SPO recently announced that it has signed with several high-profile, professional athletes who have agreed to endorse the SPO Wellness(TM) line of products. This includes the world's first performance monitoring wristband, known as the Wellness 10k(TM). The Wellness 10k(TM) is designed for both children and adults and features a display function to continuously measure the number of daily activities against preset recommended goals. Furthermore, an innovative heart-rate monitor sports watch has also been developed to measure continuous heart-rate without the need to wear a conventional chest strap, unlike many other heart-rate monitor watches that are on the market.

Both SPO Wellness(TM) products are currently at an advanced stage of development and SPO expects the Wellness 10k(TM) wristband to be launched later this month for test marketing followed by a full commercial roll-out in 2011. Braunold continued, "We believe our partnership with BSI along with the secured endorsements and our rebranding efforts will help us bring a cost-effective solution to the vast consumer wellness market, which in turn contributes to potentially increasing value for the SPO shareholders."

About SPO

SPO (SPOM) is a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-enhancing information within four key markets: medical care; sports and wellness; homecare monitoring and security. Its patented technology uses information gathered from the reflectance of light on the human body, in a noninvasive manner, to monitor key vital signs. The company manufactures its products in addition to licensing its technologies to appropriate client corporations for commercialization and distribution. For more information, visit

Forward Looking Statements

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, market acceptance of our products and new product applications, timing of new product launches, success of the Company's rebranding program, product performance, size of prospective markets, revenues assessments, success of our restructured operations and plans, our ability to generate fees or raise capital to support our business operations and plan, the sufficiency and availability of working capital, changes in economic conditions generally and in more specifically, the introduction of competing products, changes in our operating strategy or development plans patent protection for our products and technologies, changes in economic conditions generally and in more specifically, in the markets we operate, changes in technology, legislative or regulatory changes that affect us and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2009. We undertake no obligation to revise or update any forward-looking statement for any reason.


Twitter: Facebook: Contacts regarding this release: Michael Braunold, Chief Executive Officer +1-866-991-7766

SOURCE SPO Medical Inc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015 WellStar Health System has ... Texas -based Tenet Healthcare,s five metro ... approved the strategic move following the conclusion of the ... clinical care models and patient safety programs that have ... to new communities. --> ...
(Date:12/1/2015)... , Dec. 1, 2015  Eyeon Therapeutics has ... dry eye treatments based on a charged hydrophilic ... delivery CDMO.  The product has been shown to ... previously published.  Mark Mitchnick , MD, CEO ... protection to additional polymers in conjunction with a ...
(Date:12/1/2015)... 1, 2015 Pharma Tech Outlook recently conducted ... Clinical Data Management Solution Providers - 2015 .  After ... comprising CEOs, CIOs, VCs, analysts, and the Pharma Tech ... of top 10 clinical data management solution providers (check ... 14 and 36 respectively). --> ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 ... of the company’s growing product line of food safety and seafood fraud prevention ... (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for the ...
(Date:12/1/2015)... ... December 01, 2015 , ... The workstation ... lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s first portable DICOM-calibrated ... from November 29 to December 4, 2015. , MED-TAB is expected to ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... is everything. That is why Hollister Incorporated has launched the VaPro Plus Pocket™ ... next product in the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... has been awarded a fixed price per sprint agile development contract to support ... $34 million over five years, provides software engineering, infrastructure, as well as operations ...
(Date:12/1/2015)... , ... December 01, 2015 , ... XTC Semifinals ... 10 semi-finalists to head to Las Vegas for CES 2016, the world’s largest Consumer ... of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, and ...
Breaking Medicine News(10 mins):